Biosenta's Tri-Filler(TM) Nanoparticles Achieve 100% Killing of Pathogens at Industry-Low Dose in Peer-Reviewed Studies

Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles
Toronto, Ontario and Calgary, Alberta--(Newsfile Corp. - June 11, 2025) - Biosenta Inc. (CSE: ZRO) ("Biosenta") today announced that two independent, peer-reviewed studies conducted at the University of Calgary confirmed that its proprietary Tri-Filler™ core-shell calcium hydroxide-calcium carbonate (CSCC™) nanoparticles achieved complete (100 %) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.
"Transforming a readily available mineral into a durable, broad-spectrum antimicrobial opens new opportunities for safer surfaces in hospitals, transit systems and homes," said Dr. Mehdi Mohammadi Ashani, lead author of both papers.
Key laboratory findings
The research, conducted and independently validated by University of Calgary scientists, is detailed in two recent peer-reviewed publications in Colloids and Surfaces A and The Canadian Journal of Chemical Engineering.¹ ²
These studies confirmed Tri-Filler's™ potent efficacy against multiple World Health Organization priority bacterial pathogens, including:
Gram-negative bacteria: Escherichia coli (E. coli), Pseudomonas aeruginosa
Gram-positive bacteria: Staphylococcus aureus (including MRSA)
These findings were validated using both Minimum Inhibitory Concentration (MIC) and Minimum Biocidal Concentration (MBC) protocols, with consistent 100% elimination rates at the 2.5 mg/mL threshold across these bacterial strains. Traditional biocides rely on frequent re-application and can trigger resistance or toxicity. The 100 % kill rates reported above were obtained under controlled laboratory conditions.
In addition, Biosenta has obtained similar promising results against other significant microbes, including the Gram-positive bacterium Enterococcus faecalis and fungi Candida auris and Candida albicans. These results are currently under preparation for peer-reviewed publication.
"Achieving 100 per cent eradication across three WHO-priority species by a more environmentally friendly biocide at such relatively low dose moves Tri-Filler™ into a class of its own and is a decisive step toward safer, longer-lasting antimicrobial surfaces," added Dr. Maen Husein, professor of chemical and petroleum engineering and senior author of the papers.
From personal loss to public good
Biosenta's president and CEO Am Gill lost his uncle to a hospital-acquired infection. That tragedy drives the company's mission and underpins a $140-thousand donation to the Alberta Centre for Advanced Diagnostics to accelerate nanoparticle research.
"We're turning grief into action," Gill said. "Embedding Tri-Filler™ into concrete, paint and coatings will let us stop pathogens at the surface and save lives."What happens next
Regulatory filings - Health Canada and U.S. EPA submissions for Tri-Filler™-enabled products are in preparation.
Manufacturing scale-up - Bench output already tops 170 kg day; full commercial plant design is under way.
About Biosenta Inc.
Biosenta Inc. develops innovative antimicrobial products that offer environmentally friendly solutions to a global market. Based in Toronto, Ontario and Calgary, Alberta, the company is dedicated to the advancement of technology that combats microbial growth in various materials. Biosenta's flagship product, Tri-Filler®, represents a breakthrough in antimicrobial technology, providing durable protection against a wide spectrum of bacteria, molds, and fungi.
For further inquiries, please contact:
Am Gill, President and CEO, Biosenta Inc.Email: info@biosenta.comPhone: 416-410-2019
For more information, visit our website: www.biosenta.com
References
N. Darwish, M. M. Ashani, A. Mehairi, I. A. Lewis, M. M. Husein, "Synthesis of uniform core-shell calcium hydroxide-calcium carbonate biocidal particles via encapsulation into dry ice," Canadian Journal of Chemical Engineering, 2025, 1. DOI: 10.1002/cjce.25670.
N. Darwish, M. M. Ashani, I. A. Lewis, M. M. Husein, "Controlled carbonation of Ca(OH)₂ surface and its application as an antibacterial particle," Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2024, 682. DOI: 10.1016/j.colsurfa.2023.132852.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of applicable securities laws ("forward-looking statements"), including forward-looking statements relating the completion of the Transaction. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. If any such risks actually occur, they could impact the potential for discussion, agreement or completion of the Transaction and/or materially adversely affect the Company's business, financial condition or results of operations. In that case, the trading price of the Company's common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management's current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.
Disclaimer
The CSE has in no way passed upon the contents of this news release and further, has neither approved nor disapproved of the contents of this news release. Neither the CSE nor its Regulation Services Provider (as such term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255262

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

USA Today

an hour ago

• USA Today

A new COVID variant is spreading in the US: What are the symptoms?

A new COVID-19 variant that was unheard of just months ago is now projected to be the second-most common strain in the U.S. Variant NB.1.8.1 was first detected in China in January but accounted for about 0% of cases in the U.S. until May. By early June, it was estimated to account for up to 37%, according to the U.S. Centers for Disease Control (CDC). The World Health Organization (WHO) evaluated the additional public health risk posed by the variant as "low at the global level in a May report, in which it also advised that currently approved COVID-19 vaccines are "expected to remain effective to this variant against symptomatic and severe disease." Here's what we know about NB.1.8.1. 'Razor blade throat': What to know about COVID-19 variant NB.1.8.1 What is NB.1.8.1? NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent right now, Subhash Verma, microbiology and immunology professor at the University of Nevada, Reno, previously told USA TODAY in May. The new variant was first detected in January in China. As of mid-May, the variant had reached 10.7% of global reported COVID-19 cases, according to the World Health Organization (WHO). Verma previously said NB.1.8.1 may be able to be transferred more easily than LP.8.1. Additionally, he said that NB.1.8.1 is able to evade antibodies created by vaccines or past infections more easily than LP.8.1. "NB.1.8.1 is likely to spread more rapidly and evade our immune defenses more easily than LP.8.1, which is why this variant requires careful monitoring," Verma said. How common is NB.1.8.1? For a two-week period starting on May 25 and ending on June 7, the CDC's Nowcast estimates tracker shows projections for the different COVID-19 variants. According to the latest CDC data, the NB.1.8.1 strain is projected to be the second highest in the U.S., making up 37% of the total cases recorded in the U.S. The most common strain is LP.8.1, also known as Omicron, which accounts for 38% of cases, followed by NB.1.8.1 with 37%, XFG with 8%, XFC making up 7%, and LF.7.9 with 4%. The prominence of NB.1.8.1 in the U.S. has significantly increased in recent weeks, accounting for 0% of cases through March before reaching 2% in April, 5% in early May and 15% by late May. What are the symptoms of NB.1.8.1? The CDC has not outlined symptoms that are specific to the NB.1.8.1. variant. Verma said that NB.1.8.1 symptoms appear similar to those of earlier COVID-19 variants. However, an extremely sore throat, colloquially called "razor blade throat," has been associated with the new variant. People with the variant have reported a feeling akin to their throats being covered with razor blades, according to the Los Angeles Times, Fox News, SF Gate, and other news outlets. Many people have also taken to social media to describe the "razor blade throat." The CDC outlines the following as common COVID-19 symptoms: The CDC advises seeking medical care if you experience any of the following symptoms: How can you protect yourself from NB.1.8.1 and other variants? The World Health Organization states that currently approved COVID-19 vaccines are expected to remain effective against the NB.1.8.1 variant. In a webpage dated Jan. 7, 2025, the CDC advises that everyone over the age of six months get the 2024-2025 COVID-19 vaccine, specifically the 2024-2025 Moderna COVID-19 Vaccine. It also suggests that people who have never received a COVID-19 vaccine, are age 65 and older, are immunocompromised, live at a long-term care facility, are pregnant, breastfeeding, trying to get pregnant, and/or want to avoid getting long COVID, should get the vaccine, especially. However, Health and Human Services Secretary Robert F. Kennedy Jr. said on May 27 that the COVID-19 vaccine would no longer be included in the CDC's recommended immunization schedule for healthy children and pregnant women, a move that broke with previous expert guidance and bypassed the normal scientific review process. Under the changes, the only people who will be recommended for COVID-19 vaccines are those over 65 and people with existing health problems. This could make it harder for others who want the COVID-19 vaccine to get it, including health care workers and healthy people under 65 with a vulnerable family member or those who want to reduce their short-term risk of infection. This could mean that some who still wish to receive the vaccine may have to pay out of pocket, if they are able to access it at all. It is not yet known how accessible the COVID-19 vaccine will be moving forward. How to (still) get a COVID-19 test for free Increasing Community Access to Testing, Treatment and Response (ICATT), a federal program, continues to provide free COVID-19 testing to individuals without health insurance. According to the CDC, as of May 27, more than 19,000 locations across the country offer free testing. To find a location near you that offers free testing, visit

Business Wire

2 hours ago

• Business Wire

Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases

MIAMI & OAKLAND, Calif.--(BUSINESS WIRE)-- Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. 'By leveraging Fabric Genomics' high-quality clinical gene panel interpretation to support Galatea's polygenic risk score reporting, we are enabling more personalized assessments of an individual's risk for common diseases,' said Martin Reese. The initial offering will include an inherited cardiovascular gene panel based on American Heart Association (AHA) recommendations, with additional PRS for cardiovascular related traits, including coronary arterial disease, high low-density lipoprotein (LDL), elevated triglycerides, low high-density lipoprotein (HDL), atrial fibrillation, hypertension, type 2 diabetes and hypothyroidism. A follow-up offering will integrate hereditary cancer panels with PRS for breast, colorectal, and prostate cancers. 'Galatea Bio is committed to making common genetic risk prediction more accurate for all,' said Carlos Bustamante, Ph.D., CEO & Co-Founder, Galatea Bio. 'Through our collaboration with Fabric Genomics, we're working to capture both rare and common genetic contributions to disease risk—delivering meaningful insights to individuals across the US and around the world.' This collaboration integrates Fabric Genomics' platform for clinical reporting and its expertise in clinical gene panel curation with Galatea Bio's advanced PRS algorithms. By combining these capabilities, the partnership provides both rare variant and polygenic genetic risk reporting using the Broad Clinical Lab's (BCL) Blended Genome - Exome. A key component of this collaboration is the integration of Galatea Bio's newly released individually-adjusted PRS solution, StrataRisk™ PRS, which provides genetic risk for individuals of all ancestries. This is made possible through a novel, proprietary algorithm that leverages data from the Galatea Bio Global Biobank to calibrate PRS scores against similar individuals in genomic ancestry space, ensuring equitable risk assessment across diverse populations. 'By leveraging Fabric Genomics' high-quality clinical gene panel interpretation to support Galatea's polygenic risk score reporting, we are enabling more personalized assessments of an individual's risk for common diseases,' said Martin Reese, Ph.D., President of Fabric Genomics. 'This combined approach allows us to better explain patients' results with a more accurate risk profile.' Evaluating both rare genetic disease variants and polygenic risk scores can have several advantages over reporting either of these independently. Traditional single-gene or multi-gene panel testing focuses on high-penetrance rare mutations, which capture a subset of patients with an inherited single gene disease and often results in negative or uncertain results, leaving many patients' risk unexplained. PRS, which aggregates the cumulative effect of numerous common genetic variants, can provide refined risk stratification. 'This collaboration between Fabric Genomics and Galatea Bio is enabled by our clinical Blended Genome - Exome,' said Niall Lennon, Ph.D., Chief Scientific Officer, Broad Clinical Labs. 'This is exactly the kind of application we envisioned for this cost-effective approach—one that will provide a more comprehensive view of genetic susceptibility to important common diseases.' About Fabric Genomics Fabric Genomics, a GeneDx company, is democratizing genomics-driven precision medicine. The company provides institutions with end-to-end clinical sequencing solutions that include the Fabric Enterprise software platform, assay design and validation support and the clinical interpretation services needed to scale genetic testing. At the core of this platform is a suite of sophisticated AI algorithms and data knowledge systems that turn data into expert clinical insights. Headquartered in Oakland, California, Fabric Genomics supports clinical applications across a variety of use cases including rare disease, oncology, cardiovascular, neurological and women's health. To learn more, visit and follow us on X and LinkedIn. About GeneDx At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery and improve health system efficiencies. For more information, please visit and connect with us on LinkedIn, Facebook and Instagram. About Galatea Bio Galatea Bio is an innovative, venture-backed biotechnology company that strives to advance 'Precision Health at Scale for All.' Founded by pioneers in the fields of population genetics and bioinformatics, Galatea Bio leverages cutting-edge ancestry algorithms to scale the promise of precision health to global populations, while maintaining a strong commitment to ethical research. The company is headquartered in Miami Lakes, Florida. For more information, visit or follow us on X and LinkedIn. About the Broad Clinical Labs Broad Clinical Laboratories was founded in 2013 as a non-profit subsidiary of Broad Institute of MIT and Harvard to accelerate the world toward a better understanding, diagnosis and treatment of disease by pursuing projects, developing products and driving adoption of cutting edge genomics technologies and novel molecular assays. Broad Clinical Labs is a leader in translational genomics, having sequenced over 700,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease. Forward Looking Statements This press release may contain 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business combinations, plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the 'Risk Factors' section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

Yahoo

3 hours ago

• Yahoo

This dieting approach may be more effective than intermittent fasting, scientists say

Alternate-day fasting works better at boosting metabolism compared to both calorie restriction and intermittent fasting, a new study suggests. Nearly 2.5 billion adults, or about 43 per cent of the global adult population, are overweight, with around 890 million living with obesity, according to the World Health Organization. Doctors recommend weight loss for this segment of the population to reduce metabolic risk factors like high blood pressure, elevated cholesterol and increased blood sugar levels, all of which contribute to diabetes and heart disease. Intermittent fasting, which involves cycling between periods of eating and fasting on a regular schedule, is sometimes recommended as an alternative to traditional calorie-restricted diets for weight loss. This may include time-restricted eating, typically involving a 16-hour fasting period followed by an eight-hour eating window. Another form of fasting is alternate-day fasting, which involves a 24-hour fast every other day. But the health benefits of various forms of fasting compared to continuous caloric restriction and an unrestricted diet have remained largely unclear so far. In a new study, researchers analysed the results of 99 randomised clinical trials involving 6,582 adult men and women to compare the effects of intermittent fasting diets with continuous calorie restriction or unrestricted diets on body weight and metabolic risk factors. The study participants had an average body mass index of 31, and nearly 90 per cent had pre-existing health conditions. Researchers found that alternate-day fasting was the only dietary strategy which provided a modest benefit in reducing body weight compared to continuous calorie restriction. This form of fasting was also associated with lower levels of total and LDL, or 'bad' cholesterol compared to time-restricted eating. However, researchers noted that even alternate-day fasting did not meet the clinically significant threshold of at least 2kg of weight loss for individuals with obesity. They cautioned that 'longer-duration trials are needed to further substantiate these findings'. 'Additional high quality randomised clinical trials, with extended durations beyond 52 weeks, are needed to elucidate the long-term effects of these dietary strategies,' they said in the study, 'with greater emphasis between intermittent fasting and its impact on cardiometabolic health across diverse populations.' For now, they said, alternate-day fasting could be added to the therapeutic toolkit for managing weight and metabolic health. 'Intermittent fasting does not aim to replace other dietary strategies, but to integrate and complement them within a comprehensive, patient-centered nutritional care model,' they noted.